News

Exploring Amgen's Strategic Moves in the Options Market

Exploring Amgen's Strategic Moves in the Options Market

Exploring Trends in Amgen's Options Trading

Investors are making noteworthy moves in the options market for Amgen (NASDAQ: AMGN), indicating a curious bearish sentiment among high-value traders.

This behavior piques interest among retail traders, particularly when unusual trading activity surfaces from sources we monitor.

While we cannot determine whether these moves are made by institutional investors or affluent individuals, significant trading volume often signals that informed entities are predicting market shifts for AMGN.

Recent data indicates that 12 unconventional options trades were executed for Amgen, revealing a complex market sentiment.

These large-money traders exhibit a divided perspective, with approximately 33% maintaining a bullish outlook while 50% adopt a bearish stance.

Insights from Recent Trading Activity

It's essential to analyze the broader implications of these trades. Specifically, we noted that among the various options highlighted, 2 trades were puts, amounting to $67,500, while 10 were calls, with a total value of $496,525.

Forecasting Amgen's Price Targets

Based on the observed trading strategies, it appears that significant investors are eyeing a price range of $260 to $340 for Amgen within the next few months. This target market reflects a strategic assessment of potential stock movements.

Understanding Volume and Open Interest

Analyzing volume and open interest offers valuable insights into the liquidity associated with Amgen's options. This crucial data can facilitate a comprehensive understanding of fluctuating interest and liquidity at competitive strike prices.

In the past 30 days, we've been tracking the evolution of Amgen's call and put volumes, focusing specifically on whales operating within the $260 to $340 strike price range.

Amgen's Options Activity in Focus

The recent options activity illustrates a diverse set of strategic trades:

  • Symbol: AMGN, PUT/CALL: CALL, Trade Type: SWEEP, Sentiment: NEUTRAL, Expiration Date: 03/21/25, Total Trade Price: $94.6K, Volume: 55.
  • Symbol: AMGN, PUT/CALL: CALL, Trade Type: TRADE, Sentiment: BEARISH, Expiration Date: 03/07/25, Total Trade Price: $91.8K, Volume: 42.
  • Symbol: AMGN, PUT/CALL: CALL, Trade Type: TRADE, Sentiment: BEARISH, Expiration Date: 07/18/25, Total Trade Price: $64.8K, Volume: 10.
  • Symbol: AMGN, PUT/CALL: CALL, Trade Type: SWEEP, Sentiment: BEARISH, Expiration Date: 12/19/25, Total Trade Price: $43.5K, Volume: 20.
  • Symbol: AMGN, PUT/CALL: CALL, Trade Type: TRADE, Sentiment: BEARISH, Expiration Date: 06/20/25, Total Trade Price: $41.2K, Volume: 28.

About Amgen

Amgen stands at the forefront of biotechnology, specializing in innovative human therapeutics. Their primary medications include erythropoietin stimulants such as Epogen and Aranesp, alongside crucial immune system agents like Neupogen and Neulasta. They also offer treatments for inflammatory diseases, including Enbrel and Otezla. Additionally, Amgen has made substantial strides in oncology with products like Vectibix, Prolia, Xgeva, and recently introduced therapies such as Repatha for cholesterol management and Aimovig for migraines.

Current Standing of Amgen in the Market

  • Currently, AMGN trades at $316.85, up by approximately 1.95% with a volume of 1,336,050 shares.
  • Technical indicators suggest that the stock may be nearing an overbought condition.
  • The next earnings report is anticipated in roughly 58 days.

Market Analyst Opinions on Amgen

Two analysts have recently shared their views on Amgen, highlighting a consensus target price of $302. Some analysts remain bullish, with one maintaining an Overweight rating at a target of $329. Meanwhile, another analyst holds a more cautious stance, rating it Underperform with a lower target of $275.

Engaging in options trading can be riskier, but offers participants the potential for considerable returns. Traders can navigate these waters by embracing continuous learning, making methodical trade adjustments, employing a variety of indicators, and being attuned to market fluctuations. Stay updated on Amgen's options activity through platforms that provide real-time alerts for enhanced trading strategies.

Frequently Asked Questions

What does current sentiment around Amgen's options indicate?

The current sentiment reflects approximately 33% bullish and 50% bearish, suggesting investors are divided about the stock's future.

What price range are investors targeting for Amgen?

Investors appear to be targeting a price range of $260 to $340 based on recent analysis of options trading.

How can volume and open interest help investors?

Volume and open interest are essential to gauge liquidity and interest at specific strike prices, providing insight into potential future movements.

What are Amgen's most prominent drugs?

Key products include Epogen, Aranesp, Neupogen, Neulasta, Enbrel, Otezla, and more recent therapies like Repatha and Aimovig.

What are analysts saying about Amgen right now?

Analysts are currently divided, with target prices ranging from $275 to $329, with differing outlooks on the stock's performance.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

WhiteHorse Set to Redeem Its 2028 Notes Completely

Updated Category News Views 54

WhiteHorse Finance Divests Its 7.875% Notes Well, WhiteHorse Finance is making some moves, folks. They're planning to redeem their 7.875% notes due in 2028, totaling a cool $34.5 million. This ain't just pocket change, especially with the way markets have been bobbing and weaving lately. The redemption is slated for December 15, 2026, when the notes will get delisted from...

Continue Reading
Leqembi Pen Revolutionizes Alzheimer's Care in Japan

Updated Category News Views 59

Innovative Alzheimer's Treatment Hits Japanese Market Just when you think the medical world needs a jolt of innovation, BioArctic rolls out something that could change how Alzheimer's is managed. With their subcutaneous Leqembi Pen, they've just added another feather in their cap, launching in Japan after a successful U.S. introduction. Not just your run-of-the-mill...

Continue Reading
Canadian Solar Gears Up for Q3 2026 Earnings Call

Updated Category News Views 44

Canadian Solar Prepares for Earnings Disclosure Well, strap in, folks. Canadian Solar Inc. (NASDAQ: CSIQ)—a staple in the solar arena—announced that they'll unveil their third quarter 2026 financials on December 3. It's going to be a call worth dialing into. They're holding it right at 8:00 a.m. Eastern Time. You can pop over to their website for a live webcast or go...

Continue Reading
Walmart Tops 2026 Recall List: 81 Notices, Food Issues Lead

Updated Category News Views 50

Walmart Behind 81 Recalls: Scrutinizing 2026's Top Contender For an outfit that prides itself on shaking up shopping carts coast to coast, Walmart's stumble onto the recall hotseat this year is a head-scratcher. Imagine leading with 81 official recalls—that's more than a flash in the pan, it's the whole frying pan catching fire. Target and Costco aren't slouches, but...

Continue Reading
FDA Greenlights AI for Brain Aneurysm Detection

Updated Category News Views 179

Unveiling UPTUNITY: A New AI Solution Well, ain't that something? Bracco and Avicenna.AI just got the FDA's nod for their latest creation, UPTUNITY. It's like giving radiologists a trusty sidekick to spot those sneaky brain aneurysms. This ain't just another gizmo; it's a game-changer in medical imaging, giving AI a real shot at transforming how these medical sleuths do...

Continue Reading
Agiloft Navigates New Growth Phase with Key Leadership

Updated Category News Views 132

Leadership Shifts Steer Agiloft's EMEA Journey Agiloft's latest shake-ups in leadership signal a determined charge through EMEA's bustling markets. Nick Bowles, a seasoned veteran in enterprise software, steps into the limelight as Senior Vice President, while Jim Leason shifts gears into a customer-focused advisory role. These aren’t just routine hiring...

Continue Reading
Backdoor Reference Checks: A Hiring Minefield?

Updated Category News Views 78

What's Really Happening with Job References? Every job seeker has been there, right? You're all set, resume polished to a shine, references lined up like a choir ready to sing your praises, and then bam—you hear that employers are contacting folks you never listed. A new report from Zety highlights this eyebrow-raising trend, and it's got us all questioning the value...

Continue Reading
TagMaster To Acquire Kapsch's RFID Ops in NA Market

Updated Category News Views 91

A Strategic Move in the Transportation Sector Here's a fresh shake-up for the North American transportation sector: TagMaster, alongside its U.S. subsidiary Sensys Networks, is all set to acquire Kapsch TrafficCom's RFID-focused North American components business. This isn't just a minor shuffle—this deal could ripple through the industry, promising strategic uplifts...

Continue Reading
Diwali Celebration in Chicago Honors Indian Community

Updated Category News Views 142

Chicago's Diwali Tribute: Music, Dance, and Diversity Talk about spreading the glow! On November 13, 2026, Cook County Treasurer Maria Pappas is gearing up to throw a Diwali bash that'll light up Chicago's cultural landscape. Alongside Indian Consul General Dr. M. Anand Prakash, she's orchestrating a vibrant affair designed to spotlight Indian American community leaders...

Continue Reading
55 Broad Street's New Face: A $500M Revamp with RXR

Updated Category News Views 126

Recapitalization: Changing the Game for 55 Broad Street Here we are again, watching yet another iconic Manhattan building redefine itself. This time, it's 55 Broad Street's turn, as Silverstein, MetroLoft, and RXR shake things up. Newmark Group, Inc. (NASDAQ: NMRK), the fiery real estate power player, orchestrated a dynamic transaction involving a $305 million financing...

Continue Reading

Top 5 Most Recently Viewed Articles

DraftKings Faces SEC Charges Over Disclosure Practices

Updated Category News Views 110

SEC Charges DraftKings Over Selective Information Disclosure DraftKings Inc. (NASDAQ: DKNG) shares experienced slight declines in after-hours trading following a significant announcement from the U.S. Securities and Exchange Commission (SEC). The SEC has accused the company of selectively disclosing material, nonpublic information to a limited group of investors who were...

Continue Reading
Strategic Acquisition Enhances Safe & Green's Portfolio Growth

Updated Category News Views 240

Safe & Green Holdings Corp. Welcomes New Opportunity MIAMI -- Safe & Green Holdings Corp. (NASDAQ: SGBX), renowned for its innovative modular structures, is excited to announce a significant strategic move. The firm's wholly owned subsidiary, Olenox Corp., has recently acquired a controlling stake of 51% in Winchester Oil and Gas, LLC. This acquisition marks a pivotal...

Continue Reading
Q2 Holdings CFO Appointment Signals Stability in Leadership

Updated Category News Views 168

Q2 Holdings Appoints New CFO, Jonathan Price On a recent Monday, DA Davidson announced it would maintain a Neutral rating for Q2 Holdings (NYSE: QTWO) with a consistent price target of $76.00. This decision comes in light of a major executive shift at Q2 Holdings, emphasizing the company's commitment to strong leadership. Introducing Jonathan Price Jonathan Price is set...

Continue Reading
IN8bio's Upcoming Presentation at a Major Health Conference

Updated Category News Views 145

Exciting Developments at IN8bio IN8bio, Inc. (Nasdaq: INAB), a pioneering force in developing gamma-delta T cell therapies, is making headlines as it prepares for a significant event. William Ho, the company's CEO and co-founder, has announced he will present at the TD Cowen 45th Annual Health Care Conference. This important event will take place on a Monday morning, and...

Continue Reading
Actia AI Unveils Business-Centric Collaborative AI Platform

Updated Category News Views 23

Actia AI Introduces Practical AI Solutions We've heard a lot of chatter about AI's potential, but Actia AI's latest roll-out really caught my attention. Here we have a company looking to bridge the gap between revolutionary tech and everyday business, without the usual smoke and mirrors. Launched on June 30, 2026, from Emeryville, California, this platform screams...

Continue Reading